Background: Malignant pleural effusion (MPE) is the most common complication of advanced NSCLC. Infusion chemotherapy is currently one of the most common intracavitary treatments for MPE. Unfortunately, there is no de...Background: Malignant pleural effusion (MPE) is the most common complication of advanced NSCLC. Infusion chemotherapy is currently one of the most common intracavitary treatments for MPE. Unfortunately, there is no definitive consensus on which intracavitary infusion drug has the best effect on the treatment. The use of de-platinum-based thoracic perfusion therapy can offer several advantages, such as reducing drug toxicity and contributing to an improvement in patients’ physical condition. Therefore, this study was to investigate the clinical efficacy and safety of de-platinum-based pleural perfusion bevacizumab combined with Brucea Javanica Oil Emulsion Injection (BJOEI) in the treatment of malignant pleural effusion in advanced lung adenocarcinoma. Methods: A total of 60 patients diagnosed with lung adenocarcinoma and malignant pleural effusion were selected from Binzhou People’s Hospital, Shandong Provincial Cancer Hospital, and Binzhou Central Hospital between June 2022 and May 2024, with 30 cases treated in each group. The study was divided into two groups: the treatment group received bevacizumab injection perfusion in combination with intravenous infusion of Brucea Javanica Oil Emulsion Injection (BJOEI), while the control group received bevacizumab injection combined with cisplatin perfusion. To analyze the data and evaluate their efficacy and adverse reactions, such as disease control rate (DCR), overall response rate (ORR), Karnofsky Performance Status (KPS), vascular endothelial growth factor (VEGF), and so forth. Results: Following the treatment, the quality of life scores in both groups exhibited an increase compared to pre-treatment levels. Moreover, the enhancement observed in the treatment group was deemed statistically significant (P = 0.007). Following treatment, The expression of VEGF in the pleural effusion of both groups of patients was significantly decreased, and the disparity within the same group was found to be statistically significant (P P χ2 = 0.317, P = 0.573;χ2 = 0.218, P = 0.640). A stratified analysis of factors influencing the ORR revealed that the ORR in both groups exhibited statistical significance when the previous KPS score was below 70 (χ2 = 5.850, P = 0.016). The main adverse reactions in both groups included nausea, vomiting, gastrointestinal reactions, fatigue, and hematological toxicity. Among them, there was a statistically significant difference in the occurrence of gastrointestinal reactions and fatigue between the two groups (χ2 = 8.148, P = 0.004;χ2 = 6.696, P = 0.010). Conclusion: Bevacizumab, when combined with Brucea Javanica Oil Emulsion Injection (BJOEI), demonstrates noteworthy efficacy in treating malignant pleural effusion. This combination therapy reduces VEGF expression, in which the reduction supports the efficacy of thoracic perfusion and is associated with minimal adverse reactions, contributing to an improvement in patients’ physical condition and overall clinical tolerability, especially for the poor physique, especially in the elderly and KPS score is less than 70. Therefore, it can be considered a recommended approach for managing malignant pleural effusion, offering significant clinical value.展开更多
Both brain injury and tacrolimus have been reported to promote the regeneration of injured peripheral nerves. In this study, before transection of rat sciatic nerve, moderate brain contusion was（or was not） induced....Both brain injury and tacrolimus have been reported to promote the regeneration of injured peripheral nerves. In this study, before transection of rat sciatic nerve, moderate brain contusion was（or was not） induced. After sciatic nerve injury, tacrolimus, an immunosuppressant, was（or was not） intraperitoneally administered. At 4, 8 and 12 weeks after surgery, Masson＇s trichrome, hematoxylin-eosin, and toluidine blue staining results revealed that brain injury or tacrolimus alone or their combination alleviated gastrocnemius muscle atrophy and sciatic nerve fiber impairment on the experimental side, simultaneously improved sciatic nerve function, and increased gastrocnemius muscle wet weight on the experimental side. At 8 and 12 weeks after surgery, brain injury induction and/or tacrolimus treatment increased action potential amplitude in the sciatic nerve trunk. Horseradish peroxidase retrograde tracing revealed that the number of horseradish peroxidase-positive neurons in the anterior horn of the spinal cord was greatly increased. Brain injury in combination with tacrolimus exhibited better effects on repair of injured peripheral nerves than brain injury or tacrolimus alone. This result suggests that brain injury in combination with tacrolimus promotes repair of peripheral nerve injury.展开更多
BACKGROUND Maturity-onset diabetes of the young(MODY)is the most common monogenic type of diabetes.Recently,14 gene mutations have been found to be associated with MODY.In addition,the KLF11 gene mutation is the patho...BACKGROUND Maturity-onset diabetes of the young(MODY)is the most common monogenic type of diabetes.Recently,14 gene mutations have been found to be associated with MODY.In addition,the KLF11 gene mutation is the pathogenic gene of MODY7.To date,the clinical and functional characteristics of the novel KLF11mutation c.G31A have not yet been reported.CASE SUMMARY We report of a 30-year-old male patient with a one-year history of nonketosisprone diabetes and a 3-generation family history of diabetes.The patient was found to carry a KLF11 gene mutation.Therefore,the clinical data of family members were collected and investigated.A total of four members of the family were found to have heterozygous mutations in the KLF11 gene c.G31A,which resulted in a change in the corresponding amino acid p.D11N.Three patients had diabetes mellitus,and one patient had impaired glucose tolerance.CONCLUSION The heterozygous mutation of the KLF11 gene c.G31A(p.D11N)is a new mutation site of MODY7.Subsequently,the main treatment included dietary interventions and oral drugs.展开更多
Background Rupture of unstable plaque with subsequent thrombus formation is the common pathophysiological substrate of acute coronary syndrome （ACS）. It is of potential significance to explore the blood indexes pred...Background Rupture of unstable plaque with subsequent thrombus formation is the common pathophysiological substrate of acute coronary syndrome （ACS）. It is of potential significance to explore the blood indexes predicting plaque characteristics. We investigated the relationship among soluble CD105, hypersensitive C-reactive protein （hs-CRP）, and coronary plaque morphology.Methods A clinical study from April 2004 to December 2006 was conducted in 130 patients who were divided into 3 groups： 56 patients （43.1%） in stable angina （SA） group, 52 patients （40.0%） in unstable angina （UA） group and 22 patients （16.9%） in acute myocardial infarction group. The concentrations of soluble CD105 and hs-CRP were measured in all of the patients by cardioangiography （CAG）. Plasma samples of arterial blood were collected prior to the procedure. The levels of soluble CD105 and hs-CRP were measured by enzyme-linked immunosorbent assay （ELISA）.Results Unstable and ruptured plaque was found more frequently in patients with acute myocardial infarction and UA. External elastic membrane cross-sectional area （EEM CSA）, plaque area, lipid pool area and plaque burden were significantly larger in the ruptured and unstable plaque group. Positive remodeling, thinner fabric-cap, smaller minimal lumen cross-sectional area （MLA）, dissection and thrombus were significantly more frequent in the ruptured and unstable plaque group. Remodeling index （RI） was positively correlated with the levels of soluble CD105 in the UA group （r=0.628, P〈0.01） and the acute myocardial infarction group （r=0.639, P〈0.01）. The levels of soluble CD105 and hs-CRP were higher in the ruptured plaque group. Soluble CD105 〉4.3 ng/ml was used to predict ruptured plaque with a receiver operating characteristic （ROC） curve area of 0.77 （95% confidence interval （CI）, 66.8%-87.2%）, a sensitivity of 72.8%, a specificity of 78.0% and an accuracy of 70.2% （P〈0.01）, similarly for hs-CRP 〉 5.0 mg/ml with a ROC curve area of 0.70 （95% CI, 59.2%-80.2%）, a sensitivity of 70.2%, a specificity of 76.2% and an accuracy of 67.2% （P〈0.01）.Conclusions The plaque characteristics correlate with the clinical presentation. The elevation of soluble CD105 and hs-CRP is related to the plaque instability and rupture.展开更多
To the Editor:Since the first IgE monoclonal antibody was approved by the Food and Drug Administration in the USA in 2003,at least 14 kinds of targeted drugs are in the clinical application or pre-clinical trials.The ...To the Editor:Since the first IgE monoclonal antibody was approved by the Food and Drug Administration in the USA in 2003,at least 14 kinds of targeted drugs are in the clinical application or pre-clinical trials.The two monoclonal antibodies targeting IgE are omalizumab and ligelizumab.Four drugs targeting interleukin 4(IL-4)or IL-4R are pascolizumab,pitrakinra,altrakincept,and dupilumab.Three monoclonal antibodies targeting IL-5/IL-5R are mepolizumab,reslizumab,and benralizumab.Two monoclonal antibodies targeting IL-13 are lebrikizumab and tralokinumab.The monoclonal antibody targeting thymic stromal lymphopoietin(TSLP)is tezepelumab.Th2 cytokine inhibitor is mesylate.These targeted drugs have achieved good results,but most of them are still in the pre-clinical stage.This article reviews the history,marketing situation,indications,contraindications,efficacy,and safety of these targeted drugs.展开更多
文摘Background: Malignant pleural effusion (MPE) is the most common complication of advanced NSCLC. Infusion chemotherapy is currently one of the most common intracavitary treatments for MPE. Unfortunately, there is no definitive consensus on which intracavitary infusion drug has the best effect on the treatment. The use of de-platinum-based thoracic perfusion therapy can offer several advantages, such as reducing drug toxicity and contributing to an improvement in patients’ physical condition. Therefore, this study was to investigate the clinical efficacy and safety of de-platinum-based pleural perfusion bevacizumab combined with Brucea Javanica Oil Emulsion Injection (BJOEI) in the treatment of malignant pleural effusion in advanced lung adenocarcinoma. Methods: A total of 60 patients diagnosed with lung adenocarcinoma and malignant pleural effusion were selected from Binzhou People’s Hospital, Shandong Provincial Cancer Hospital, and Binzhou Central Hospital between June 2022 and May 2024, with 30 cases treated in each group. The study was divided into two groups: the treatment group received bevacizumab injection perfusion in combination with intravenous infusion of Brucea Javanica Oil Emulsion Injection (BJOEI), while the control group received bevacizumab injection combined with cisplatin perfusion. To analyze the data and evaluate their efficacy and adverse reactions, such as disease control rate (DCR), overall response rate (ORR), Karnofsky Performance Status (KPS), vascular endothelial growth factor (VEGF), and so forth. Results: Following the treatment, the quality of life scores in both groups exhibited an increase compared to pre-treatment levels. Moreover, the enhancement observed in the treatment group was deemed statistically significant (P = 0.007). Following treatment, The expression of VEGF in the pleural effusion of both groups of patients was significantly decreased, and the disparity within the same group was found to be statistically significant (P P χ2 = 0.317, P = 0.573;χ2 = 0.218, P = 0.640). A stratified analysis of factors influencing the ORR revealed that the ORR in both groups exhibited statistical significance when the previous KPS score was below 70 (χ2 = 5.850, P = 0.016). The main adverse reactions in both groups included nausea, vomiting, gastrointestinal reactions, fatigue, and hematological toxicity. Among them, there was a statistically significant difference in the occurrence of gastrointestinal reactions and fatigue between the two groups (χ2 = 8.148, P = 0.004;χ2 = 6.696, P = 0.010). Conclusion: Bevacizumab, when combined with Brucea Javanica Oil Emulsion Injection (BJOEI), demonstrates noteworthy efficacy in treating malignant pleural effusion. This combination therapy reduces VEGF expression, in which the reduction supports the efficacy of thoracic perfusion and is associated with minimal adverse reactions, contributing to an improvement in patients’ physical condition and overall clinical tolerability, especially for the poor physique, especially in the elderly and KPS score is less than 70. Therefore, it can be considered a recommended approach for managing malignant pleural effusion, offering significant clinical value.
基金supported by a grant from the Mandatory Project of Health Department of Hebei Province of China,No.20130027a grant from the Mandatory Project of Science and Technology Department of Hebei Province of China,No.142777105Da grant from Science and Technology Bureau of Chengde City of Hebei Province of China,No.20123128
文摘Both brain injury and tacrolimus have been reported to promote the regeneration of injured peripheral nerves. In this study, before transection of rat sciatic nerve, moderate brain contusion was（or was not） induced. After sciatic nerve injury, tacrolimus, an immunosuppressant, was（or was not） intraperitoneally administered. At 4, 8 and 12 weeks after surgery, Masson＇s trichrome, hematoxylin-eosin, and toluidine blue staining results revealed that brain injury or tacrolimus alone or their combination alleviated gastrocnemius muscle atrophy and sciatic nerve fiber impairment on the experimental side, simultaneously improved sciatic nerve function, and increased gastrocnemius muscle wet weight on the experimental side. At 8 and 12 weeks after surgery, brain injury induction and/or tacrolimus treatment increased action potential amplitude in the sciatic nerve trunk. Horseradish peroxidase retrograde tracing revealed that the number of horseradish peroxidase-positive neurons in the anterior horn of the spinal cord was greatly increased. Brain injury in combination with tacrolimus exhibited better effects on repair of injured peripheral nerves than brain injury or tacrolimus alone. This result suggests that brain injury in combination with tacrolimus promotes repair of peripheral nerve injury.
文摘BACKGROUND Maturity-onset diabetes of the young(MODY)is the most common monogenic type of diabetes.Recently,14 gene mutations have been found to be associated with MODY.In addition,the KLF11 gene mutation is the pathogenic gene of MODY7.To date,the clinical and functional characteristics of the novel KLF11mutation c.G31A have not yet been reported.CASE SUMMARY We report of a 30-year-old male patient with a one-year history of nonketosisprone diabetes and a 3-generation family history of diabetes.The patient was found to carry a KLF11 gene mutation.Therefore,the clinical data of family members were collected and investigated.A total of four members of the family were found to have heterozygous mutations in the KLF11 gene c.G31A,which resulted in a change in the corresponding amino acid p.D11N.Three patients had diabetes mellitus,and one patient had impaired glucose tolerance.CONCLUSION The heterozygous mutation of the KLF11 gene c.G31A(p.D11N)is a new mutation site of MODY7.Subsequently,the main treatment included dietary interventions and oral drugs.
文摘Background Rupture of unstable plaque with subsequent thrombus formation is the common pathophysiological substrate of acute coronary syndrome （ACS）. It is of potential significance to explore the blood indexes predicting plaque characteristics. We investigated the relationship among soluble CD105, hypersensitive C-reactive protein （hs-CRP）, and coronary plaque morphology.Methods A clinical study from April 2004 to December 2006 was conducted in 130 patients who were divided into 3 groups： 56 patients （43.1%） in stable angina （SA） group, 52 patients （40.0%） in unstable angina （UA） group and 22 patients （16.9%） in acute myocardial infarction group. The concentrations of soluble CD105 and hs-CRP were measured in all of the patients by cardioangiography （CAG）. Plasma samples of arterial blood were collected prior to the procedure. The levels of soluble CD105 and hs-CRP were measured by enzyme-linked immunosorbent assay （ELISA）.Results Unstable and ruptured plaque was found more frequently in patients with acute myocardial infarction and UA. External elastic membrane cross-sectional area （EEM CSA）, plaque area, lipid pool area and plaque burden were significantly larger in the ruptured and unstable plaque group. Positive remodeling, thinner fabric-cap, smaller minimal lumen cross-sectional area （MLA）, dissection and thrombus were significantly more frequent in the ruptured and unstable plaque group. Remodeling index （RI） was positively correlated with the levels of soluble CD105 in the UA group （r=0.628, P〈0.01） and the acute myocardial infarction group （r=0.639, P〈0.01）. The levels of soluble CD105 and hs-CRP were higher in the ruptured plaque group. Soluble CD105 〉4.3 ng/ml was used to predict ruptured plaque with a receiver operating characteristic （ROC） curve area of 0.77 （95% confidence interval （CI）, 66.8%-87.2%）, a sensitivity of 72.8%, a specificity of 78.0% and an accuracy of 70.2% （P〈0.01）, similarly for hs-CRP 〉 5.0 mg/ml with a ROC curve area of 0.70 （95% CI, 59.2%-80.2%）, a sensitivity of 70.2%, a specificity of 76.2% and an accuracy of 67.2% （P〈0.01）.Conclusions The plaque characteristics correlate with the clinical presentation. The elevation of soluble CD105 and hs-CRP is related to the plaque instability and rupture.
基金the Major Project of Hainan Province(No.ZDKJ2016008)the Key Project of Social Development in Hainan Province and Matching Fund from Sanya City of Hainan Province(No.ZDYF2016127)the National Natural Science Foundation of China(Nos.81371074,81670901).
文摘To the Editor:Since the first IgE monoclonal antibody was approved by the Food and Drug Administration in the USA in 2003,at least 14 kinds of targeted drugs are in the clinical application or pre-clinical trials.The two monoclonal antibodies targeting IgE are omalizumab and ligelizumab.Four drugs targeting interleukin 4(IL-4)or IL-4R are pascolizumab,pitrakinra,altrakincept,and dupilumab.Three monoclonal antibodies targeting IL-5/IL-5R are mepolizumab,reslizumab,and benralizumab.Two monoclonal antibodies targeting IL-13 are lebrikizumab and tralokinumab.The monoclonal antibody targeting thymic stromal lymphopoietin(TSLP)is tezepelumab.Th2 cytokine inhibitor is mesylate.These targeted drugs have achieved good results,but most of them are still in the pre-clinical stage.This article reviews the history,marketing situation,indications,contraindications,efficacy,and safety of these targeted drugs.
